Prostaglandin E2 is an important modulator of airway physiology. During episodes of allergic inflammation such as in asthma, PGE2 may affect disease pathogenesis through 2 distinct pathways: by direct effects on airway tone and by modulating the intensity of the inflammatory response. These actions of PGE2 are mediated by 4 different receptors (EP1-4). In the previous funding period, we showed that activation of the EP1 and EP3 receptors by PGE2 leads to airway obstruction, while activation of the EP2 receptor protected against methacholine-induced bronchoconstriction. Moreover, EP1 and EP3 receptors are pro-inflammatory while the EP2 and EP4 receptors constrain inflammatory and immune responses. As a lipid mediator with a short half-life, regulation of PGE2 levels within specific pulmonary microenvironments could provide a mechanism to control these apparently disparate actions. PGE2 is synthesized from arachidonic acid by the sequential actions of phospholipases, cyclo-oxygenases, and PGE synthases. To date, 3 putative PGE synthases have been identified that generate PGE2 from endoperoxides. At least 1 enzyme responsible for in vivo metabolism of PGE2, 15-prostaglandin dehydrogenase (PGDH), has been identified. However, the roles of these various pathways for synthesis and metabolism of PGE2 in controlling its actions in the airways are not known. Our central hypothesis is that PGE2 primarily exerts a protective effect in allergic airway. We posit that the mechanism of this effect is: constraint of inflammation, protection against development of hyper reactive airways, and attenuation of airway remodeling. These protective effects are dependent on expression of the PGE2 EP2 and EP4 receptors. We will test this hypothesis using mouse models, some of which were developed in the previous funding period. Our preliminary studies suggest that the protective actions of PGE2 may diminish with age due to age-related increase in the pro-inflammatory PGE2 pathways. We hypothesize that the mechanism for this shift in the actions of PGE2 in older animals reflects a more prominent contribution of mast cells to promote airway inflammation. Defining the mechanisms used by PGE2 to control inflammation in the airways and developing strategies to enhance its anti-inflammatory effects should provide new approaches for attenuating the development of asthma.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL068141-06
Application #
7074751
Study Section
Special Emphasis Panel (ZRG1-RES-C (02))
Program Officer
Noel, Patricia
Project Start
2001-09-20
Project End
2010-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
6
Fiscal Year
2006
Total Cost
$354,889
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Kovarova, Martina; Koller, Beverly H (2014) PGE? promotes apoptosis induced by cytokine deprivation through EP3 receptor and induces Bim in mouse mast cells. PLoS One 9:e102948
Gruzdev, Artiom; Nguyen, MyTrang; Kovarova, Martina et al. (2012) PGE2 through the EP4 receptor controls smooth muscle gene expression patterns in the ductus arteriosus critical for remodeling at birth. Prostaglandins Other Lipid Mediat 97:109-19
Allen, Irving C; Lich, John D; Arthur, Janelle C et al. (2012) Characterization of NLRP12 during the development of allergic airway disease in mice. PLoS One 7:e30612
Cyphert, Jaime M; Allen, Irving C; Church, Rachel J et al. (2012) Allergic inflammation induces a persistent mechanistic switch in thromboxane-mediated airway constriction in the mouse. Am J Physiol Lung Cell Mol Physiol 302:L140-51
Kovarova, Martina; Koller, Beverly (2012) Differentiation of mast cells from embryonic stem cells. Curr Protoc Immunol Chapter 22:Unit 22F.10.1-16
Allen, Irving C; Jania, Corey M; Wilson, Justin E et al. (2012) Analysis of NLRP3 in the development of allergic airway disease in mice. J Immunol 188:2884-93
Church, Rachel J; Jania, Leigh A; Koller, Beverly H (2012) Prostaglandin E(2) produced by the lung augments the effector phase of allergic inflammation. J Immunol 188:4093-102
Cyphert, J M; Kovarova, M; Koller, B H (2011) Unique populations of lung mast cells are required for antigen-mediated bronchoconstriction. Clin Exp Allergy 41:260-9
Kovarova, Martina; Latour, Anne M; Chason, Kelly D et al. (2010) Human embryonic stem cells: a source of mast cells for the study of allergic and inflammatory diseases. Blood 115:3695-703
Arthur, Janelle C; Lich, John D; Ye, Zhengmao et al. (2010) Cutting edge: NLRP12 controls dendritic and myeloid cell migration to affect contact hypersensitivity. J Immunol 185:4515-9

Showing the most recent 10 out of 22 publications